This article was originally published in The Gray Sheet
Files a registration statement with the Securities and Exchange Commission proposing an offering of 2 mil. shares of common stock held by a Becton-Dickinson subsidiary. B-D obtained the shares when its Applied Biosystems holdings were exchanged into Perkin-Elmer shares as part of the two firms' merger ("The Gray Sheet" Oct. 12, 1992, p. 3). Following the proposed offering, B-D will have completely divested its interest in Perkin-Elmer, which will receive no proceeds from the transaction. "The sale of these securities is consistent with" B-D's policy "to maintain investments only in niche market companies," according to B-D President and CEO Raymond Gilmartin. First Boston Corporation will underwrite the offering.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.